EUCTR2016-001001-16-Outside-EU/EEA进行中（未招募）1 期
A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response with or without Xolair after Long-Term Therapy (XPORT) - XPORT
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed Informed Consent Form (ICF). In the case of a minor, consent must be given by the child's parent or legally authorized representative.
- •Participants who have completed the EXCELS study prior to this study must have met all inclusion criteria for enrollment in the EXCELS study.
- •History of positive skin test or in vitro reactivity to an aeroallergen.
- •Continuous Xolair (omalizumab) exposure from the beginning of the EXCELS study to randomization into this study (if the participant participated in the EXCELS study), or within the previous 5 years prior to randomization into this study (if the participant did not participate in the EXCELS study). For the purposes of this study, continuous Xolair exposure is defined as having missed no more than 25% of scheduled Xolair doses. In addition, a maximum of 2 doses can be missed within the last 6 months before being randomized into this study.
- •For participants who did not participate in the EXCELS study, missed-dose rates will be based on their injection records.
- •Patients who participated in the EXCELS study must have completed the EXCELS study and not discontinued Xolair since the completion of the EXCELS study.
- •Diagnosis of moderate to severe persistent allergic asthma while on Xolair as defined per physician's assessment.
- •Stable dosing of current asthma therapies, in addition to Xolair, over 2 months prior to enrollment.
- •Serum IgE level = 30 to = 700 IU/mL before initiation of Xolair treatment (prior to the EXCELS study enrollment or earlier).
- •Body weight = 30 to = 150 kg.
- •Treatment with Xolair consistent with the US package insert (USPI) (based on the dosing table, recommended dose, administration, and dosing interval) prior to enrollment to this study.
- •Participants who participated in the EXCELS study must be willing to allow their EXCELS study data to be used in this study as part of baseline demographic values (such as forced expiratory volume in 1 second [FEV1] and Asthma Control Test [ACT]), as documented in the ICF.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 180
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 155
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •Participation in other therapy trials or planned participation during the following year from screening.
- •Contraindication to Xolair therapy (eg, participants who experienced a severe hypersensitivity reaction to Xolair).
- •Acute asthma exacerbation within the 2 months immediately prior to screening that required any of the following: Initiation of systemic corticosteroids, increased dosing of systemic corticosteroids relative to stable dose, doubling of inhaled corticosteroid (ICS) dosing, emergency room visit, and hospitalization.
- •Any significant, or unstable, systemic disease (eg, infection, hematologic, renal, hepatic, cardiovascular diseases, or gastrointestinal diseases), or a recent hospitalization because of systemic disease within the previous 2 months.
- •Diagnosis of active lung disease other than asthma.
- •Having more than 10 pack-years smoking history.
- •Diagnosis of cystic fibrosis.
- •Use of an experimental drug within 30 days prior to study screening.
- •Unable or unwilling to comply with study procedures and visits (eg, spirometry, blood draws).
- •Have elevated serum IgE levels for reasons other than allergy (eg, parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich syndrome, or bronchopulmonary aspergillosis).
- •Pregnancy, lactation, or any planned pregnancy in the following year.
研究者
相似试验
未知
4 期
A Phase IV, Multi-centre, Randomised, Double-Blind Study to Evaluate the Efficacy and Safety of NK- 104 versus Atorvastatin in Chinese Patients with HypercholesterolaemiaJPRN-jRCT2080221598Kowa Co., Ltd.480
进行中（未招募）
1 期
A phase 4 Study to evaluate the safety and efficacy of Lesinurad 200 mg in combination with a Xanthine Oxidase Inhibitor (XOI) compared with XOI alone in subjects with gout.Gout and moderate renal impairmentMedDRA version: 20.0Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001191-30-HUIronwood Pharmaceuticals, Inc.242
进行中（未招募）
1 期
A phase 4 Study to evaluate the safety and efficacy of Lesinurad 200 mg in combination with a Xanthine Oxidase Inhibitor (XOI) compared with XOI alone in subjects with gout.Gout and moderate renal impairmentMedDRA version: 20.0Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001191-30-PLIronwood Pharmaceuticals, Inc.600
进行中（未招募）
1 期
A phase 4 Study to evaluate the safety and efficacy of Lesinurad 200 mg in combination with a Xanthine Oxidase Inhibitor (XOI) compared with XOI alone in subjects with gout.Gout and moderate renal impairmentMedDRA version: 20.0Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001191-30-CZIronwood Pharmaceuticals, Inc.600
已完成
4 期
Clinical Study to check the effectiveness and safety of KiOnutrime-CsG capsules, for weight reduction.CTRI/2014/08/004901Corona Remedies Pvt Ltd